In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Beam Therapeutics, with a price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kostas Biliouris’s rating is based on several strategic factors related to Beam Therapeutics’ position in the AATD market and their technological advancements. The management’s confidence in the competitive positioning of BEAM-302, particularly against RNA and DNA editing approaches, is a significant factor. They believe that the DNA editing efficiency of BEAM-302 is superior, with a potential for ~90%+ M-AAT levels, compared to RNA editing’s saturation at ~50-60% efficiency. This positions Beam Therapeutics favorably against competitors like WVE, whose data limitations are seen as specific to them.
Additionally, Beam Therapeutics’ focus on the US market, where they plan to target currently treated patients and improve diagnosis rates, is a strategic move. The management’s decision to delay data readout to early 2026 aims to provide a more comprehensive regulatory update, enhancing clarity on the BEAM-302 pathway. Furthermore, the company is not currently seeking partnerships for BEAM-302, indicating their confidence in its potential as a primary value-creation lever in the near term. These elements collectively contribute to the Buy rating given by Kostas Biliouris.
In another report released on September 3, Bank of America Securities also maintained a Buy rating on the stock with a $43.00 price target.